Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mycophenolate sodium in the treatment of corticosteroid-refractory non-infectious inflammatory uveitis (MySTRI study)



To evaluate the therapeutic effect and safety profile of next generation mycophenolate sodium (MPS), which is different from mycophenolate mofetil with an enteric-coated formulation, in corticosteroid-refractory non-infectious inflammatory uveitis (CRU) patients.


Prospective, uncontrolled, open-label interventional case series. Forty consecutive patients at a tertiary uveitis referral centre received 6 months of oral MPS as the treatment regimen with follow-up 12 months. The main outcome measures were best-corrected visual acuity (BCVA), inflammatory index, steroid-sparing effect of tapering prednisone to ≤10 mg daily and side effects.


Mean age of enroled patients was 49 (49 ± 13) years and 29 (72.5%) were female. Thirty-six (90.0%) had bilateral disease. There were 0 (0%) anterior uveitis, 2 (5.0%) intermediate uveitis, 22 (55.0%) posterior uveitis, and 16 (40.0%) panuveitis. Vogt-Koyanagi-Harada disease was the most common diagnosis (17/40, 42.5%), followed by idiopathic panuveitis (8/40, 20%) and idiopathic retinal vasculitis (5/40, 12.5%). LogMAR BCVA improved from 0.9 (SD = 0.09) to 0.31 (SD = 0.08) after 6 months of MPS with good steroid-sparing effect (p = 0.012). Further maintenance in LogMAR BCVA was evident after MPS discontinuation from 6th month to 12th month, from 0.31 (SD = 0.08) to 0.33 (SD = 0.07), respectively (p = 0.81). MPS was the only immunosuppressive drug needed to reach quiescent state in 29 patients (72.5%). The drug-related safety profile was satisfactory.


MPS is an effective steroid-sparing drug for the treatment of CRU. The effect seen was not only during the 6 months of therapy, but also extended to 12 months to maintain BCVA and inflammation control. The side effects were acceptable.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Best-corrected visual acuity of the patients over the study period.
Fig. 2: Anterior chamber and vitreous cells SUN grading of the patients over the study period.
Fig. 3: Central foveal thickness of the patients over the study period.
Fig. 4: Steroid-sparing effect of mycophenolate sodium over the study period.


  1. 1.

    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–6.

    CAS  Article  Google Scholar 

  2. 2.

    Jones NP. The Manchester Uveitis Clinic: the first 3000 patients, 2: Uveitis Manifestations, complications, medical and surgical management. Ocul Immunol Inflamm. 2015;23:127–34.

  3. 3.

    Hughes EH, Dick AD. The pathology and pathogenesis of retinal vasculitis. Neuropathol Appl Neurobiol. 2003;29:325–40.

    CAS  Article  Google Scholar 

  4. 4.

    Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS. Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet’s disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol. 2002;130:46–54.

    CAS  Article  Google Scholar 

  5. 5.

    Nussenblatt R. Treating intraocular inflammatory disease in the 21st century. Arch Ophthalmol. 2005;123:1000–1.

    Article  Google Scholar 

  6. 6.

    Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev. 2005;4:144–52.

    CAS  Article  Google Scholar 

  7. 7.

    Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357–9.

    CAS  Article  Google Scholar 

  8. 8.

    Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370–4.

    CAS  Article  Google Scholar 

  9. 9.

    Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061–5.

    Article  Google Scholar 

  10. 10.

    Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472–7.

    Article  Google Scholar 

  11. 11.

    Shen E, Rathinam SR, Babu M, Kanakath A, Thundikandy R, Lee SM, et al. Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. Am J Ophthalmol. 2016;168:279–86.

    Article  Google Scholar 

  12. 12.

    Budde K, Bauer S, Hambach P, Hahn U, Roblitz H, Mai I, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transpl. 2007;7:888–98.

    CAS  Article  Google Scholar 

  13. 13.

    Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507–15.

    CAS  Article  Google Scholar 

  14. 14.

    Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transpl. 2004;4:237–43.

    CAS  Article  Google Scholar 

  15. 15.

    Lee PC, Chang SS, Shieh SC, Wu ZC, Wang WM, Wang JD, et al. Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? Transpl Proc. 2012;44:137–9.

    CAS  Article  Google Scholar 

  16. 16.

    Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transpl. 2007;21:18–23.

    Article  Google Scholar 

  17. 17.

    Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.

    Article  Google Scholar 

  18. 18.

    O’Neill TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behcet’s disease. Br J Rheumatol. 1994;33:115–7.

    Article  Google Scholar 

  19. 19.

    Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.

    CAS  Article  Google Scholar 

  20. 20.

    Doycheva D, Zierhut M, Blumenstock G, Sobolewska B, Voykov B, Hohmann J, et al. Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood. Br J Ophthalmol. 2016;100:1071–5.

    Article  Google Scholar 

  21. 21.

    Deuter CME, Engelmann K, Heiligenhaus A, Lanzl I, Mackensen F, Ness T, et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br J Ophthalmol. 2018;102:647–53.

    Article  Google Scholar 

  22. 22.

    Doycheva D, Jagle H, Zierhut M, Deuter C, Blumenstock G, Schiefer U, et al. Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. Br J Ophthalmol. 2015;99:87–91.

    Article  Google Scholar 

  23. 23.

    Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brezin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative. Ophthalmology. 2018;125:757–73.

    Article  Google Scholar 

  24. 24.

    Herbort CP Jr, Abu El Asrar AM, Takeuchi M, Pavésio CE, Couto C, Hedayatfar A, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol. 2019;39:1419–25.

    Article  Google Scholar 

Download references


CMRPG3B0441, CORPG3C0081.

Author information



Corresponding author

Correspondence to Yih-Shiou Hwang MD, PhD.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Medical Ethics Committee approval # NCT01261169, Chang Gung Memorial Hospital.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, T.S., Tsang, W.M., Enkh-Amgalan, I. et al. Mycophenolate sodium in the treatment of corticosteroid-refractory non-infectious inflammatory uveitis (MySTRI study). Eye 34, 2098–2105 (2020).

Download citation


Quick links